Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
about
Severe thrombocytopenia possibly related to readministration of eptifibatide.Drug-induced and drug-dependent immune thrombocytopenias.Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug.Profound thrombocytopenia associated with tirofiban: case report and review of literature.Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.Acute profound thrombocytopenia with second exposure to eptifibatide associated with a strong antibody reactionThrombocytopenia following percutaneous coronary intervention.Actual Role of Platelet Glycoprotein IIb/IIIa Receptor Inhibitors as Adjunctive Pharmacological Therapy to Primary Angioplasty in Acute Myocardial Infarction: In the Light of Recent Randomized Trials and Observational Studies with Bivalirudin.Profound delayed thrombocytopenia presenting 16 days after Abciximab (Reopro®) administration.Profound thrombocytopenia after primary exposure to eptifibatide.Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immediately after left main coronary artery percutaneous coronary angioplasty.Pseudothrombocytopenia in a patient receiving romiplostim for immune thrombocytopenic purpura.Chronic subdural hematoma in elderly patient with EDTA-dependent pseudothrombocytopenia recently treated with aspirin and warfarin: case reportAcute Severe Thrombocytopenia Occurring After Administration of Eptifibatide Postpones Emergent Coronary Artery SurgeryLotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment.Abciximab: a review and update for clinicians.Therapeutic monoclonal antibodies and clinical laboratory tests: When, why, and what is expected?Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen.Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study.Delayed, severe thrombocytemia after abciximab infusion for primary angioplasty in acute coronary syndromes: Moving between systemic bleeding and stent thrombosis.A Case of Hyperacute Severe Thrombocytopenia Occurring Less than 24 Hours after Intravenous Tirofiban Infusion.
P2860
Q33338960-C06F6E3A-3594-4827-A9C4-0C568420F283Q33339739-78FF609E-0B5D-49A3-9856-3416671328BCQ33360759-806901D6-E330-4258-9A2C-AA60982E2DF9Q33366275-F7C82A56-5B6C-4E43-9157-32015A0A6DF5Q33370200-49C6303B-5A87-49C9-B964-2F710155A69CQ33382937-FE4EAEB0-093B-48B1-BB08-4C4733545C5FQ33387648-C3EBE01B-3102-4B2B-BEC2-00F7E38DC0DBQ33391341-66CD478A-389A-4BDE-8369-62F234DFF92CQ33395086-528CE14A-6415-4CC8-8619-D3B9F9022F55Q33395925-2840E681-1355-483B-898C-0F884E669408Q33400223-ACFB42A6-25E3-4F1D-A749-0761646F8444Q33410641-A0192FC5-1147-4DAB-B631-6A0AD52AEE12Q33413027-ECC87BBB-A2FE-46DC-BE81-3768675660B3Q33436741-4C85BF64-D211-4431-9CAD-357C845EC7D4Q34075194-F03F1208-EB57-45F5-99E9-E42461A8A9BDQ35008537-BF3F821D-C095-4319-85DD-944620F5FC01Q37176419-D7124007-ECB6-477E-9184-54C4C4F51C09Q38623790-0FECFA8E-2FE1-4FEB-B14E-FE67D0091418Q43956494-36E54551-EAEA-463D-AE97-9B6D2D629364Q48444889-FD7C77FD-E89D-4D1B-AA90-A0DC485185CCQ53587801-5E0D52BF-D104-4BE5-878F-3A90499654B8Q55442994-93959779-080B-4005-B672-5B314D67AAFD
P2860
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
@ast
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
@en
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
@nl
type
label
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
@ast
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
@en
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
@nl
prefLabel
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
@ast
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
@en
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
@nl
P2093
P1476
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
@en
P2093
L V Damaraju
M A Mascelli
M L Simoons
R A Harrington
P356
10.1016/S0735-1097(00)00688-4
P407
P577
2000-07-01T00:00:00Z